# Melanotan 2 Side Effects Documented in Research — Adverse Events and Safety Signals

> Melanotan 2 side effects documented in published clinical trials, case reports, and pharmacovigilance literature — renal, cardiovascular, dermatological, and sexual adverse events. Cited summaries.

The Melanotan 2 side effects record comes from two sources: the Phase I/II clinical trials and a growing body of case reports describing adverse events in unregulated self-administration contexts. MT-II has not been approved by any regulatory authority. No systematic human safety study exists.

## Adverse Events in Published Clinical Trials

Dorr 1996 (n=3) at 0.01–0.025 mg/kg SC: spontaneous penile erections lasting 1–5 hours, transient nausea, somnolence, fatigue. [1] Wessells 1998 (n=10) at 0.025 mg/kg: transient nausea, yawning, decreased appetite. [2] Wessells 2000 (n=20): severe nausea in 12.9% at 0.025 mg/kg. [3]

## Safety Signals Documented in the Research Literature

Published case reports document renal infarction, melanoma, dysplastic nevus transformation, and priapism. Regulatory agencies TGA (Australia) and MHRA (UK) have issued enforcement warnings. Gilhooley 2021: qualitative study of 623 forum posts from 205 users, identified pigmented lesions, unsterile-injection infection, polydrug interactions. [7] Deville 2024: forensic analysis confirmed ~30% purity in tested illicit MT-II vials. [17]

## Renal Observations with Melanotan 2

Peters 2020: 45-year-old male, right-sided renal infarction affecting ~50% of kidney tissue after 27 mg MT-II SC over six months. [4] First published renal infarction case in Swedish Poison Center's 215 MT-II exposure records.

## Melanocytic and Dermatological Adverse Events

- Sivyer 2012: 16-year-old female with FAMMM syndrome developed dysplastic melanocytic nevi including moderate cytoarchitectural atypia after MT-II + UV tanning; pigmentation reversed 3 months post-cessation. [8]
- Hjuler and Lorentzen 2014: histologically confirmed melanoma at gluteal region, 20-year-old woman, MT-II + tanning beds. [9]
- Hueso-Gabriel 2012: eruptive dysplastic nevi following MT-II use in patient with dysplastic nevus history. [20]

## Priapism: A Serious Sexual Adverse Event

Mallory 2021: acute ischemic priapism requiring surgical penoscrotal decompression after cavernosal aspiration, irrigation, and intracavernous phenylephrine failed. [10] Third published case. Ischemic priapism is a urological emergency — resolution within 4–6 hours required to prevent permanent damage.

## References

[1] Dorr RT et al. Life Sciences. 1996;58(20):1777-1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
[2] Wessells H et al. Journal of Urology. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
[3] Wessells H et al. International Journal of Impotence Research. 2000;12 Suppl 4:S74-S79. https://pubmed.ncbi.nlm.nih.gov/11035391/
[4] Peters B et al. CEN Case Reports. 2020;9(2):150-153. https://pmc.ncbi.nlm.nih.gov/articles/PMC7148395/
[7] Gilhooley E et al. Dermatology. 2021;237(6):966-975. https://pubmed.ncbi.nlm.nih.gov/34464955/
[8] Sivyer GW. Dermatology Practice and Concept. 2012;2(3):202a10. https://pubmed.ncbi.nlm.nih.gov/23785612/
[9] Hjuler KF, Lorentzen HF. Dermatology. 2014;228(1):34-36. https://pubmed.ncbi.nlm.nih.gov/24355990/
[10] Mallory CW et al. Sexual Medicine. 2021;9(1):100298. https://pubmed.ncbi.nlm.nih.gov/33460908/
[17] Deville M, Charlier C. Journal of Forensic Sciences. 2024;69(6):2192-2199. https://pubmed.ncbi.nlm.nih.gov/39302005/
[20] Hueso-Gabriel L et al. Actas Dermosifiliogr. 2012;103(8):740-742. https://pubmed.ncbi.nlm.nih.gov/22425244/

---

An editorial reading of the peer-reviewed Melanotan 2 record — Phase I trials, preclinical mechanism studies, and pharmacovigilance case reports, indexed to source.